Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants. Issue 7 (August 2022)

• Record Type: Journal Article
• Authors: Shah, Ishani; Silva-Santisteban, Andy; Germansky, Katharine A.; Kandasamy, Cinthana; Mlabasati, Jack; Huang, Dora C.; Wadhwa, Vaibhav; Bilal, Mohammad; Sawhney, Mandeep S.
• Is Part Of: Pancreas. Volume 51:Issue 7(2022)
• Page Start: 733
• Page End: 738
• Publication Date: 2022-08
• Subjects: BRCA -- family history -- pancreatic cancer -- screening; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000002104
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: Current guidelines limit pancreatic cancer screening to those BRCA1/2 patients who have a family history of pancreatic cancer. We aimed to assess the association between family history and risk of pancreatic neoplasms in BRCA1/2 patients. Methods: We reviewed medical records of BRCA1/2 patients followed at our institution between 1995 and 2020. Family history was defined as those with a first-degree relative with pancreatic cancer. We compared the incidence and prevalence of pancreatic neoplasms between patients with and without family history of pancreatic cancer. Results: We identified 56 BRCA1/2 patients with family history and 238 without family history of pancreatic cancer. No difference between these groups was noted in age, race, or sex. Mean follow-up interval for BRCA1/2 patients was 4.6 years (range, 0–19.7 years). There was no significant difference in prevalence (19.6% vs 12.6; P = 0.3) or incidence (29% vs 14.1%; P = 0.08) of branch-duct intraductal papillary mucinous neoplasm between the 2 groups. No association between family history and pancreatic cancer risk was noted. Only 1 of 10 BRCA1/2 patients with pancreatic cancer had a family history. Conclusions: Our results do not support using family history to determine eligibility for pancreatic cancer screening.